• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Medidata, Syapse Partner to Democratize Access to Oncology Clinical Trials

by Fred Pennic 02/01/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Syapse

Medidata, a provider of cloud-based technology and data analytics for clinical research, and Syapse, a precision medicine solutions provider, have announced a new partnership to transform oncology clinical trials for the age of precision medicine. As part of the new partnership, Medidata and Syapse will jointly develop a portfolio of solutions to make it easier for cancer patients to access potentially life-saving clinical trials,

Partnership Details

The partnership will initially build products to assist trial sponsors in designing eligibility criteria, identify community health systems as trial sites, and enable oncologists and their care teams to easily identify patients for enrollment into cutting-edge clinical trials.

Medidata’s solutions power clinical trials for 18 of the world’s top 25 pharmaceutical companies, and Syapse solutions power precision medicine for nearly 300 hospitals across 25 states. The partnership aims to bring these products to pharmaceutical companies and health systems at scale over the coming years.

In 2017, the approval of novel drugs in the U.S. hit a 21-year high, with many targeting rare diseases and types of cancer. The continued growth of precision medicine compounds the challenges of finding the right patients for the right trials in oncology. This approach segments populations based on both traditional clinical factors and novel molecular characteristics, thus reducing population sizes for targeted therapy and immunotherapy trials.

“Syapse and Medidata are coming together to democratize access to clinical trials for patients across the country,” said Ken Tarkoff, CEO of Syapse in a statemnet. “The many targeted cancer therapies in development today can save patients’ lives, but only if we improve clinical trials so they reach the patients who can benefit from them. Syapse and Medidata are uniquely positioned to tackle this problem, at an unparalleled scale, because of our combined partnerships with community health systems and life sciences companies.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Cancer Big Data, Clinical Trials, Evidence-based medicine, Medidata, Precision Medicine, Precision Medicine Oncology, Syapse

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |